Evidence map›Paper›PMID 25756679›Full record

ArticleThe ISME journal2015

Clostridium difficile heterogeneously impacts intestinal community architecture but drives stable metabolome responses.

David Rojo, María J Gosalbes, Rafaela Ferrari, Ana E Pérez-Cobas, Ester Hernández, Rosa Oltra, Javier Buesa, Amparo Latorre, Coral Barbas, Manuel Ferrer and 1 more

Abstract read
In one paragraph

Article in The ISME journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. The emerging view on the roles of butyrate inInfection and immunity · 2025
    Review
  3. Pathogens (Basel, Switzerland) · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Gut Microbiota Composition Associated withPathogens (Basel, Switzerland) · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Metabolomics reveals synergy between Ag and g-CMetabolomics : Official journal of the Metabolomic Society · 2021
    Article
  13. Review
  14. Article
  15. Article
  16. mSphere · 2018
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

David RojoCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad CEU San Pablo, Campus Montepríncipe, Madrid, Spain.
María J GosalbesUnidad Mixta de Investigación en Genómica y Salud de la Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO) and Instituto Cavanilles de Biodiversidad y Biología Evolutiva de la Universidad de Valencia, Valencia, Spain.
Rafaela FerrariUnidad Mixta de Investigación en Genómica y Salud de la Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO) and Instituto Cavanilles de Biodiversidad y Biología Evolutiva de la Universidad de Valencia, Valencia, Spain.
Ana E Pérez-CobasUnidad Mixta de Investigación en Genómica y Salud de la Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO) and Instituto Cavanilles de Biodiversidad y Biología Evolutiva de la Universidad de Valencia, Valencia, Spain.
Ester HernándezCSIC, Institute of Catalysis, Madrid, Spain.
Rosa OltraUnidad Enfermedades Infecciosas, Servicio Medicina Interna, Hospital Clínico Universitario de Valencia-INCLIVA, Valencia, Spain.
Javier BuesaDepartamento de Microbiología, Facultad de Medicina, Universidad de Valencia and Hospital Clínico Universitario de Valencia-INCLIVA, Valencia, Spain.
Amparo LatorreUnidad Mixta de Investigación en Genómica y Salud de la Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO) and Instituto Cavanilles de Biodiversidad y Biología Evolutiva de la Universidad de Valencia, Valencia, Spain.
Coral BarbasCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad CEU San Pablo, Campus Montepríncipe, Madrid, Spain.
Manuel FerrerCSIC, Institute of Catalysis, Madrid, Spain.
Andrés MoyaUnidad Mixta de Investigación en Genómica y Salud de la Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO) and Instituto Cavanilles de Biodiversidad y Biología Evolutiva de la Universidad de Valencia, Valencia, Spain.
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESInstituto de Catálisis y Petroleoquímica · ESUniversidad San Pablo CEU · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESHospital Clínico Universitario de Valencia · ESUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clostridium difficile-associated diarrhoea (CDAD) is caused by C. difficile toxins A and B and represents a serious emerging health problem. Yet, its progression and functional consequences are unclear. We hypothesised that C. difficile can drive major measurable metabolic changes in the gut microbiota and that a relationship with the production or absence of toxins may be established. We tested this hypothesis by performing metabolic profiling on the gut microbiota of patients with C. difficile that produced (n=6) or did not produce (n=4) toxins and on non-colonised control patients (n=6), all of whom were experiencing diarrhoea. We report a statistically significant separation (P-value <0.05) among the three groups, regardless of patient characteristics, duration of the disease, antibiotic therapy and medical history. This classification is associated with differences in the production of distinct molecules with presumptive global importance in the gut environment, disease progression and inflammation. Moreover, although severe impaired metabolite production and biological deficits were associated with the carriage of C. difficile that did not produce toxins, only previously unrecognised selective features, namely, choline- and acetylputrescine-deficient gut environments, characterised the carriage of toxin-producing C. difficile. Additional results showed that the changes induced by C. difficile become marked at the highest level of the functional hierarchy, namely the metabolic activity exemplified by the gut microbial metabolome regardless of heterogeneities that commonly appear below the functional level (gut bacterial composition). We discuss possible explanations for this effect and suggest that the changes imposed by CDAD are much more defined and predictable than previously thought.

Indexed as

Bacterial ToxinsClostridioides difficileClostridium InfectionsDiarrheaFecesFemaleHumansIntestinesMaleMetabolomeMetabolomicsRNA, BacterialRNA, Ribosomal, 16SBacterial ToxinsRNA, BacterialRNA, Ribosomal, 16S

Identifiers

PMID25756679
PMCPMC4579473
OpenAlexW1965880431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.